WHO SHOULD CONSIDER THE VACCINE

You should consider vaccination if you will be visiting developing countries (especially in Central and South America, Asia, and Africa) and staying for a prolonged period of time, eating adventurously, or venturing off the usual tourist routes into small cities, villages, and rural areas. As your access to reasonable medical care decreases, the importance of vaccination increases.

WHO SHOULD NOT USE THE VACCINE

As a general rule, some people should not be vaccinated unless the benefit of the vaccine clearly outweighs the disease risk.

People suffering from a moderate or severe illness (with or without fever) should delay vaccination until they have recovered.

Oral Vaccine – Vivotif BernaTM

Because it is a live-bacteria vaccine and there is at least theoretical reason to be concerned about its effect on a developing fetus, women should only receive this vaccine during pregnancy when the journey is necessary and the risk of contracting the disease is so substantial as to outweigh the theoretical risk to the fetus.

Oral typhoid vaccine should not be given to children under 6 years of age.

Persons with altered immune status, including those with AIDS, should not receive this vaccine, nor should people with acute diarrhea or vomiting, travelers receiving sulfa medications or antibiotics, and people with a history of prior severe reaction to oral typhoid.

Injectable Vaccine – Typhim ViTM

Because the effect of this vaccine on the fetus is unknown, women should only receive it during pregnancy when the journey is necessary and the risk of contracting the disease is so substantial as to outweigh any possible risk to the fetus.

This vaccine should not be given to children less than 2 years of age.

The manufacturer warns that the vaccine's effectiveness could be lowered in persons with immune disorders or those receiving treatment that lowers their immunity.

As with any vaccine, persons who have had a prior severe reaction to Typhim ViTM should not receive it again.

Persons who have severe thrombocytopenia or any bleeding disorder should discuss their options for receiving this vaccine, which is given intramuscularly, with their health provider.